These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 21775818)

  • 1. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments.
    Witkiewicz AK; Knudsen KE; Dicker AP; Knudsen ES
    Cell Cycle; 2011 Aug; 10(15):2497-503. PubMed ID: 21775818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
    Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
    Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53.
    Chien WW; Domenech C; Catallo R; Salles G; Ffrench M
    Cell Cycle; 2010 Aug; 9(16):3286-96. PubMed ID: 20703084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
    Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
    Konecny GE; Winterhoff B; Kolarova T; Qi J; Manivong K; Dering J; Yang G; Chalukya M; Wang HJ; Anderson L; Kalli KR; Finn RS; Ginther C; Jones S; Velculescu VE; Riehle D; Cliby WA; Randolph S; Koehler M; Hartmann LC; Slamon DJ
    Clin Cancer Res; 2011 Mar; 17(6):1591-602. PubMed ID: 21278246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
    Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
    Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of Tumor Suppressor Gene CDKN2A and Encoded p16-INK4a Protein by Covalent Modifications.
    Jiao Y; Feng Y; Wang X
    Biochemistry (Mosc); 2018 Nov; 83(11):1289-1298. PubMed ID: 30482142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas.
    Kishimoto I; Mitomi H; Ohkura Y; Kanazawa H; Fukui N; Watanabe M
    J Surg Oncol; 2008 Jul; 98(1):60-6. PubMed ID: 18484097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines.
    McLaughlin-Drubin ME; Park D; Munger K
    Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16175-80. PubMed ID: 24046371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component.
    Xu G; Li JY
    J Neurooncol; 2018 Feb; 136(3):445-452. PubMed ID: 29150788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role for p16(INK4a) in progression of gastrointestinal stromal tumors of the stomach: alteration of p16(INK4a) network members.
    Mitomi H; Fukui N; Kishimoto I; Tanabe S; Kikuchi S; Saito T; Hayashi T; Yao T
    Hum Pathol; 2011 Oct; 42(10):1505-13. PubMed ID: 21496871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer.
    Zhao R; Choi BY; Lee MH; Bode AM; Dong Z
    EBioMedicine; 2016 Jun; 8():30-39. PubMed ID: 27428416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms.
    Ruas M; Gregory F; Jones R; Poolman R; Starborg M; Rowe J; Brookes S; Peters G
    Mol Cell Biol; 2007 Jun; 27(12):4273-82. PubMed ID: 17420273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
    Heilmann AM; Perera RM; Ecker V; Nicolay BN; Bardeesy N; Benes CH; Dyson NJ
    Cancer Res; 2014 Jul; 74(14):3947-58. PubMed ID: 24986516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
    Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
    Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The atr protein kinase controls UV-dependent upregulation of p16INK4A through inhibition of Skp2-related polyubiquitination/degradation.
    Al-Khalaf HH; Hendrayani SF; Aboussekhra A
    Mol Cancer Res; 2011 Mar; 9(3):311-9. PubMed ID: 21270107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma.
    Barton KL; Misuraca K; Cordero F; Dobrikova E; Min HD; Gromeier M; Kirsch DG; Becher OJ
    PLoS One; 2013; 8(10):e77639. PubMed ID: 24098593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
    McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
    Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
    Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
    Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
    Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
    Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.